GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MannKind Corp (FRA:NNFN) » Definitions » Deferred Tax

MannKind (FRA:NNFN) Deferred Tax : €0.0 Mil (TTM As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is MannKind Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

MannKind's change in deferred tax for the three months ended in Mar. 2024 was €0.0 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Mar. 2024 was €0.0 Mil.

MannKind Deferred Tax Historical Data

The historical data trend for MannKind's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MannKind Deferred Tax Chart

MannKind Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Deferred Tax
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MannKind Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MannKind Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MannKind Deferred Tax Related Terms

Thank you for viewing the detailed overview of MannKind's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

MannKind (FRA:NNFN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MannKind Corp (FRA:NNFN) » Definitions » Deferred Tax
Comparable Companies
FDMT TARS SYRE AKRO BCRX KNSA CGEM IMTX DAWN VIR OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
MNKD:USA
Address
1 Casper Street, Danbury, CT, USA, 06810
Website
https://www.mannkindcorp.com
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

MannKind (FRA:NNFN) Headlines

No Headlines